ABSCIENCES (EPA:AB) | Finanzwire

BRIEF

published on 01/22/2025 at 19:04, 1 year 3 months ago

AB Science Participates in Biomed Forum Investors Conference

Investor Conference BIOMED Forum AB Science Masitinib Protein Kinase Inhibitors
PRESS RELEASE

published on 01/22/2025 at 18:59, 1 year 3 months ago

AB Science will participate in the Biomed Forum investors conference
AB Science to participate in Biomed Forum Investors Conference organized by AllInvest Securities in Paris on February 4, 2025

Pharmaceutical Company BIOMED Forum AB Science Investors Conference AllInvest Securities
BRIEF

published on 12/17/2024 at 19:09, 1 year 4 months ago

AB Science presents the advances of AB8939 for acute myeloid leukemia

Phase 1 AB8939 Acute Myeloid Leukemia Drug Resistance Potential Market
PRESS RELEASE

published on 12/17/2024 at 19:04, 1 year 4 months ago

AB Science provides a summary of the webcast held on December 16, 2024
AB Science provides an update on AB8939, a novel microtubule destabilizer and ALDH inhibitor in phase 1 for AML treatment. Potential market size exceeded EUR 2 billion per annum

Market Potential AML Treatment AB Science Phase 1 AB8939
BRIEF

published on 10/17/2024 at 19:33, 1 year 6 months ago

AB Science Faces Setback in EMA Approval for ALS Treatment

AB Science Masitinib Marketing Authorization ALS Treatment EMA Decision
PRESS RELEASE

published on 10/17/2024 at 19:28, 1 year 6 months ago

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
AB Science provides an update on the application for conditional marketing authorisation of masitinib in the treatment of amyotrophic lateral sclerosis. EMA confirms negative opinion but company remains focused on confirmatory phase 3 program

Phase 3 Program AB Science Masitinib Amyotrophic Lateral Sclerosis Conditional Marketing Authorisation
BRIEF

published on 10/10/2024 at 08:32, 1 year 6 months ago

AB Science Reports Mid-2024 Financial Results and Clinical Developments

Financial Results Clinical Trials Capital Increase AB Science Masitinib
PRESS RELEASE

published on 10/10/2024 at 08:27, 1 year 6 months ago

AB Science: Revenues for the first half of 2024 and update on AB Science’s activities
AB Science presents financial results for the first half of 2024, updates on clinical development in ALS and MS, positive results in Covid-19 study, and intellectual property strengthening. AB announces capital increase and coverage initiations. Press Release by AB Science SA

Financial Results Capital Increase Clinical Development Intellectual Property AB Science
BRIEF

published on 09/30/2024 at 08:34, 1 year 7 months ago

AB Science announces a capital increase of 5.0 million euros

Capital Increase Clinical Development AB Science Masitinib European Investors
BRIEF

published on 09/23/2024 at 17:56, 1 year 7 months ago

AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis

Multiple Sclerosis Treatment Masitinib ECTRIMS 2024 Neurodegenerative

Published on 05/02/2026 at 00:50, 39 minutes ago

CoTec Announces Annual Stock Option, Restricted Share Unit And Deferred Share Unit Grants
Published on 05/02/2026 at 00:00, 1 hour 29 minutes ago

Redwood AI Announces Enhanced AI Models, Increasing Evaluated Chemical Reactions Following Preliminary Results from UBC Collaboration
Published on 05/02/2026 at 00:00, 1 hour 29 minutes ago

Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Published on 05/01/2026 at 22:30, 2 hours 59 minutes ago

Nextech3D.ai Appoints New Independent Auditor
Published on 05/01/2026 at 22:30, 2 hours 59 minutes ago

Integrated Rewards Achieves SOC 2 Compliance to Support Enterprise-Scale Growth Across Canada's Card-Linked Rewards Network as EQ Closes Convertible Debt Financing

View all ACCESSWIRE

Published on 05/01/2026 at 19:23, 6 hours 6 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/01/2026 at 18:40, 6 hours 49 minutes ago

Holding(s) in Company
Published on 05/01/2026 at 17:47, 7 hours 42 minutes ago

Key Figures 30.04.2026
Published on 05/01/2026 at 17:45, 7 hours 44 minutes ago

Burkhalter Group acquires Progressio Holding GmbH and anplaq ag, Tamins (GR)
Published on 05/01/2026 at 17:21, 8 hours 7 minutes ago

Fuller, Smith & Turner PLC: Total Voting Rights and Treasury Shares

View all EQS

Published on 04/30/2026 at 20:00, 1 day 5 hours ago

AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 1 day 6 hours ago

AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 1 day 6 hours ago

Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 1 day 7 hours ago

Minutes of the Combined General Meeting held on April 30, 2026
Published on 04/30/2026 at 18:00, 1 day 7 hours ago

TF1 Q1 2026 results - Press release

View all LES ECHOS COMFI WIRE

News